BioVie Inc. Class A Common Stock (BIVI)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the business. BioVie is a clinical-stage biopharmaceutical company with 13 employees, developing therapies for neurological and neurodegenerative disorders and advanced liver disease. It has no reported revenue in the filed figures, so the entire value rests on future trial outcomes, not current earnings. That is not a moat; it is a lottery ticket unless the science creates durable pricing power. The financials are weak. Return on equity is -150.76% and return on capital employed is -79.06%, both FairStock calculations. Trailing free cash flow is -$19.0 million, a -210.2% FCF yield on the 2026-10-13 market cap of $9.1 million. The Piotroski score is 0/9 and Altman Z-score is -34.57, which point to severe financial distress. At the same time, debt to equity is only 0.03, so the immediate problem is cash burn and dilution, not leverage. For fiscal 2026, the year ended 2026-06-30, net income was -$22.1 million and diluted EPS was -$3.05; fiscal 2025 net income was -$17.5 million and fiscal 2024 was -$32.1 million. The loss in each of the last four years means the computed Lynch category is none. Price at $1.20 gives a P/B of 0.88 and P/E of -0.39, but those aren't meaningful supports when earnings are negative and cash is burning. FairStock score 55/100 doesn't make it a bargain. I would need evidence of trial success, financing, and eventual revenue before calling this anything but speculative.

In plain English: BioVie is a small clinical-stage drug company working on treatments for brain and nerve diseases and serious liver disease. It has no reported product revenue and has posted losses in each of the last four years, so the business looks weak today. At $1.20 on 2026-10-13, the price is not clearly cheap or expensive because there are no profits to measure it against; it depends mostly on whether its drugs succeed in testing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer